-
STK-001-DS-501 - An Open-Label Extension Study for Patients with Dravet Syndrome who Previously Participated in Studies of STK 001
The purpose of this research study is to look at a possible new therapy for Dravet syndrome, called STK-001. Dravet syndrome is a severe form ... -
Retrain Your Brain for Healthy Eating Study
You may be eligible for The Retrain your Brain for Healthy Eating Study. Weight loss is not easy. This study is evaluating a new approach ... -
Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
The purpose of the study is to determine and to evaluate the safety as well as efficacy of investigational treatment arms with or without pembrolizumab ... -
A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer.
You can participate in this study if you are diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. The ... -
A Phase 1b/2 randomized double-blind placebo-controlled multi-center study of STMC-103H in neonates and infants at high-risk for developing allergic disease
The purpose of this research study is to evaluate the safety and effectiveness of STMC-103H. STMC- 103H is an investigational product and is a mixture ... -
A Phase 1/2 Open-label Study to Investigate the Safety Efficacy and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
This study is designed for patients diagnosed with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R/R B-ALL).
This study is a 2-part ...
-
A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C
This study is designed for patients with acute myeloid leukemia.
The study is a phase 1/2 dose escalation study of the BCL-2 Inhibitor ZN-d5 ...
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
-
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The ...
-
A Phase 1b/2a randomized double-blind placebo-controlled parallel-group dose-escalation study to investigate the safety tolerability pharmacokinetics pharmacodynamics and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies
Longboard Pharmaceuticals, Inc. has begun a study of an investigational drug called LP352 as a possible treatment for seizures associated with Developmental and Epileptic Encephalopathies ...